Christopher Roberson, MS, AGNP-BC, ACRN

• Nurse Practitioner, Baltimore, Maryland

Creatine kinase levels in rhabdomyolysis are often greater than 10 times the upper limit of normal symptoms 8 days before period 200 mg seroquel buy otc, and persons with this affliction have dark urine resulting from myoglobinuria medicine used during the civil war 50 mg seroquel order overnight delivery. Patients taking a statin should be asked to report any sign of unusual medicine naproxen order seroquel 50 mg with amex, diffuse treatment 2nd degree heart block 200 mg seroquel order mastercard, or persistent muscle tenderness treatment 2 go buy genuine seroquel, pain, or weakness, especially if it is accompanied by malaise, fever, or dark urine. Factors that increase the risk of statin-induced myopathy include higher doses, increasing age, female gender, renal or hepatic disease, hypothyroidism, and the use of drugs that inhibit statin metabolism. For example, the highest dose of simvastatin (80 mg) has been associated with a much higher incidence of myopathy and rhabdomyolysis than lower doses (10 or 20 mg). Use of the statin must be discontinued if myopathy is diagnosed or if levels of creatine kinase are found to be significantly elevated. No specific treatment exists for rhabdomyolysis except drug withdrawal and fluid administration to maintain renal function. For example, they increase warfarin levels slightly by inhibiting warfarin metabolism. Because statins, fibric acid derivatives, and niacin may cause myopathies, the combined use of drugs should be undertaken with great caution using lower doses of each agent employed. Bile Acid­Binding Resins Cholestyramine, colestipol, and colesevelam are bile acid­binding resins that are moderately effective drugs for hypercholesterolemia and have an excellent safety record. They are especially valuable for patients who cannot tolerate other drugs and for younger patients who may need to have drug therapy for many years. Chemistry and Pharmacokinetics the bile acid­binding resins are high-molecular-weight polymers containing a chloride ion that can be exchanged for bile acids in the gut. Mechanisms and Pharmacologic Effects After the resins bind to bile acids, the bile acid­resin complex is excreted. This action prevents the enterohepatic cycling of bile acids and obligates the liver to synthesize replacement bile acids from cholesterol. Adverse Effects and Interactions the bile acid­binding resins have few adverse effects. They can cause constipation, fecal impaction, and other gastrointestinal side effects, most of which can be prevented by taking the drugs with a full glass of water and maintaining fluid intake throughout the day. In the gut, Chapter 15 DrugsforHyperlipidemia cholestyramine and colestipol can bind to digoxin, thyroxin, warfarin, and other drugs. For this reason, it is best to take the resins 2 hours before or after taking other medications. Although the resins are less effective than the statins, they do not cause hepatitis or myopathy, and they can be given in combination with other drugs to produce an additive effect on serum cholesterol levels. The resins have also been used to treat chronic diarrhea due to bile acid malabsorption. Preparations Cholestyramine and colestipol are available as a powder for mixing with water or juice just before administration, and cholestyramine is also marketed as a chewable bar. To obtain the maximal effect on serum cholesterol levels, these drugs must be taken before each meal and at bedtime. Colesevelam is a newer resin available as solid tablets that are usually taken twice daily with meals. Ezetimibe Ezetimibe is a unique drug that inhibits the absorption of dietary cholesterol. After oral administration, ezetimibe is absorbed from the intestines and then is metabolized to the pharmacologically active metabolite ezetimibe-glucuronide. This active metabolite is distributed by the circulation to the small intestines, where it localizes in the brush border and inhibits the absorption of both biliary and dietary cholesterol. Studies suggest that ezetimibe acts by disrupting a complex of two proteins, annexin-2 and caveolin-1, which mediate cholesterol transport in intestinal brush border cells. Because of its unique mechanism of action, ezetimibe can be used alone or in combination with a statin to treat hypercholesterolemia. A fixed-dose combination of ezetimibe and simvastatin (Vytorin), and ezetimibe with atorvastatin (Liptruzet) are available for this purpose. This combination has been found to be effective in treating persons with homozygous familial hypercholesterolemia. Ezetimibe is generally well tolerated, though it can increase serum hepatic transaminase levels, and some persons experience headache and myalgia. The small amount of niacin that is ingested in food is converted in the body to enzyme cofactors required for oxidative reactions in the metabolism of energy substrates and other substances. Fibric Acid Derivatives from the gut and is extensively metabolized before undergoing renal excretion. Mechanisms and Pharmacologic Effects the quantity of niacin ingested in food does not have any measurable effect on serum lipid levels. The action of niacin on lipids is a pharmacologic effect that requires the administration of large doses (several grams) of the compound each day. The Coronary Drug Project found that niacin reduced the risk of myocardial infarction among men with hypercholesterolemia and atherosclerosis, and it decreased total mortality. Niacin is also used to reduce the risk of pancreatitis in patients with very high triglyceride levels. It is the only antilipemic drug with a consistent ability to reduce lipoprotein (a) levels, and it has been used for this purpose. Adverse Effects and Interactions the large doses of niacin required to lower serum lipids typically cause vasodilation and flushing of the skin accompanied by pruritus and a feeling of warmth and tingling. This effect can be reduced by pretreatment with aspirin, and some tolerance to this effect develops with continued drug administration. These effects are also reduced with the use of a sustained-release niacin preparation. In a small percentage of patients, niacin can elevate serum transaminase levels and cause hepatitis. Although niacin can increase blood glucose and aggravate diabetes, clinical trials show it can be Chemistry and Pharmacokinetics these drugs are derivatives of a branched-chain carboxylic acid known as fibric acid or fibrate. The first drug in this class, clofibrate, is no longer available because of its high incidence of adverse effects. Gemfibrozil and fenofibrate are currently available in the United States and many other countries. Indications Gemfibrozil and fenofibrate are indicated for the treatment of very high triglyceride levels (higher than 1,500 mg/dL) to prevent pancreatitis when dietary therapy has failed to lower these levels. The benefit of treating moderately elevated triglyceride levels is less clear, and lifestyle changes such as weight loss and exercise can lower such levels in many patients. Most clinical trials have found that fibrates do not significantly lower the rates of fatal myocardial infarction or total mortality. In a Chapter 15 DrugsforHyperlipidemia trial of fenofibrate in patients with type 2 diabetes and mixed dyslipidemia, fenofibrate did not reduce the rates of either fatal or nonfatal myocardial infarction. For this reason, some authorities suggest using niacin, rather than a fibrate, to control dyslipidemia in patients who have not responded to other drugs. Leptin Deficiency Leptin is a peptide hormone released by adipose tissue that transmits information about energy stores to the brain and other organs. In patients with lipodystrophy, the lack of adipose tissue leads to a deficiency of leptin and hypertriglyceridemia with deposition of fat in nonadipose tissue such as the liver and muscle. The lack of leptin signal also leads to excessive calorie intake and further metabolic dysfunction such as insulin resistance. Metreleptin is an analog of human leptin hormone, differing by only one amino acid substitution with methionine, and produced by recombinant biotechnology in E. Metreleptin binds to and activates the leptin receptor, leading to an increase in insulin sensitivity and reduced food intake. Drug Combinations Drugs can be used in combination to treat high blood cholesterol in patients who do not respond to a single drug. The most useful combinations are those consisting of a statin with ezetimibe or a bile acid­binding resin. For example, ezetimibe and simvastatin are available in a combination product called Vytorin, among others. Colesevelam is a newer bile acid­binding resin that can be coadministered with statins, and extended-release niacin may be added to a statin when cholesterol levels cannot be controlled with other drugs. For patients with elevated levels of both cholesterol and triglycerides, a statin can be combined with niacin or a fibrate drug. Niacin is often preferred for this purpose for several reasons: (1) niacin has a greater effect on cholesterol levels than fibrates and may enable the use of lower doses of a statin to control hypercholesterolemia; (2) clinical trials show that niacin lowers cardiovascular and overall mortality; and (3) niacin is less likely than fibrates to cause myopathy and rhabdomyolysis when used in combination with a statin. Niacin and simvastatin are combined in a formulation called Simcor for these reasons. Adverse Effects and Interactions the fibrates often cause gastrointestinal side effects and, less commonly, blood cell deficiencies and other hypersensitivity reactions. As with the statin drugs, the fibrates can cause myopathy and rhabdomyolysis (see Table 15. Fibrates can be given with cholestyramine and colestipol, but the doses must be separated by more than 2 hours, because the resins reduce fibrate absorption. Lomitapide causes gastrointestinal side effects in most patients, and it decreases the absorption of fat-soluble vitamins A, D, and E, and omega-3 fatty acids. The drug may also cause hepatic toxicity, and serum levels of hepatic enzymes should be monitored. The drug may elevate serum hepatic transaminase levels, which must be monitored, and many patients experience injection site reactions, flu-like symptoms, nausea, and headache. These agents are administered subcutaneously every 2 weeks for the treatment of homozygous or heterozygous familial hypercholesterolemia and for patients with demonstrated atherosclerotic cardiovascular disease who are not adequately treated with statins. Stimulation of lipoprotein lipase by a fenofibrate results in lowered serum levels of which substance After the vessel is repaired, the clot is removed via the process of fibrinolysis. Vasoconstriction reduces bleeding and blood flow and facilitates platelet aggregation and blood coagulation. Exposure of the blood to extravascular collagen causes adherence of platelets to the injured vessel wall and initiates the sequential activation of numerous coagulation factors (blood clotting factors), most of which are serine protease enzymes. In this cascade, the inactive factors are converted to active enzymes by the previous coagulation factor or stimulus. The intrinsic pathway can be activated by surface contact with a foreign body or extravascular tissue, whereas the extrinsic pathway is activated by a complex tissue factor. The extrinsic pathway is believed to be the most important coagulation pathway for in vivo coagulation. The pathways converge with the activation of factor X, which is the major rate-limiting step in the coagulation cascade. The activation of factor X leads to the formation of thrombin; and thrombin, in turn, catalyzes the conversion of fibrinogen to fibrin. The fibrin mesh traps erythrocytes and platelets to complete the formation of a hemostatic thrombus (clot). Thrombin formation and platelet aggregation are mutually supportive, in that platelets release thrombin to promote fibrin formation, and thrombin is a powerful stimulant of platelet aggregation. Pathologic Thrombus Formation Arterial thrombi are often overlaid on a disrupted atherosclerotic plaque that exposes blood to plaque material that initiates platelet aggregation and coagulation. Venous thrombi are usually initiated by venous blood pooling and sluggish blood flow that promotes expression of adhesion factors on the surface of venous endothelial cells. Leukocytes can adhere to these cells and release tissue factor that activates coagulation. Coagulation has a larger role than platelet aggregation in causing venous thrombi, and anticoagulants are often used to prevent venous thromboembolism. Inhibition of proteins C and S can cause a transient procoagulant effect when warfarin is first administered. Pharmacokinetic and Pharmacologic Effects Warfarin is well absorbed from the gut and extensively metabolized before being excreted in the urine. Unlike heparin and related anticoagulants, warfarin crosses the placenta and can cause fetal hemorrhage. Warfarin has a delayed onset of action owing to the time required to deplete the pool of circulating clotting factors after synthesis of new factors is inhibited. Therefore, the maximal effect of warfarin is not observed until 3 to 5 days after therapy is started. Blood coagulation involves the sequential activation of proteolytic clotting factors. The intrinsic pathway can be activated by surface contact with a foreign body, whereas the extrinsic pathway is activated by tissue factor. The pathways converge with the activation of factor X, which leads to the formation of thrombin and fibrin. A period of several days is also required for coagulation factor levels to return to normal after warfarin has been discontinued. The recovery of clotting factors can be accelerated by administration of phytonadione (vitamin K1), as described later. Adverse Effects and Interactions the most common adverse effect of warfarin is bleeding (Table 16. Patients should be instructed to report any signs of bleeding, including hematuria and bleeding into the skin (ecchymoses). Warfarin is contraindicated in pregnancy because of its potential to cause fetal hemorrhage and various structural malformations referred to as the fetal warfarin syndrome. Warfarin blocks the reduction of oxidized vitamin K (vitamin K epoxide) and thereby prevents vitamin K­dependent carboxylation of clotting factors. Warfarin and other vitamin K antagonists block this process and can cause bone deformities and various birth defects that are listed in Table 4.

Among factors that predict early mortality are the presence of frailty medications 7 rights buy 300 mg seroquel, impaired functional status treatment 1st degree burn generic seroquel 100 mg overnight delivery, low body weight or serum albumin concentration medicine 7 year program seroquel 100 mg cheap, and need for nursing care at the time of dialysis initiation symptoms 16 dpo order discount seroquel line. A recent review has highlighted the limits and deficiencies of the most commonly used prognostic tools treatment 7 seroquel 100 mg on-line. Compared with the early 2000s, patients are older and more medically complex235 with more than 50% being older than 65 years and 25% older than 75 years. Others benefit from socialization with staff and other patients at the dialysis facility and from having frequent contact with the dialysis staff to provide both medical and psychosocial support. Additional challenges include the creation and maintenance of vascular access, problems associated with postdialysis recovery time, such as fatigue, and the risk of falls after dialysis. Transplantation offers survival benefits across all ages, although due to the attendant risks of the surgery itself and side effects associated with immunosuppressive drugs, patients have an increased mortality risk in the initial few months. Survival equivalence, as compared with maintenance dialysis, is seen approximately 8 months after the surgery is performed in younger patients257 but not seen in those aged 70 years and older until more than 10 months have elapsed from the date of transplantation. Older patients are at higher risk of medication-related adverse events and higher rates of opportunistic infections and neoplasia. Single-center studies from Europe and Australia have suggested that a substantial number of older patients with advanced kidney disease are treated conservatively and do not receive dialysis. Ideally a multidisciplinary renal team, patient, and family should be present and information shared about the potential benefits and harms of the various treatment options. Discussions should be specific to the individual and his or her lifestyle and values. It is important that patients and key individuals in their social network have realistic expectations of life with the different treatment options. Helping patients and families to be part of a problem-solving approach to individualized management will maximize treatment benefits. An interdisciplinary team consisting of multiple professionals, including physicians, nurses, pharmacists, physiotherapists, occupational therapists, speech-language pathologists, social workers, psychologists, dietitians, and recreation therapists, work together, often with overlapping roles, to provide interventions such as therapeutic exercises, fall prevention plans, education on ways to conserve energy during activity, and recommendations of assistive devices. It is also an opportune moment to initiate or pursue discussions around goals of care and advance care planning. Providing dialysis in short daily sessions, if feasible, may improve the success of the program. Short daily dialysis (6 times/week for 2 hours) is well tolerated, limits scheduling conflicts and interference between medical and rehabilitation treatments, and may lead to improved nutrition and better participation in therapy sessions. Patients report less fatigue and fewer symptoms associated with rapid fluid shifts. In this series, more than 70% of patients met functional goals and showed clinically meaningful improvements in personal independence. Nephrologists may collaborate with the rehabilitation team to reevaluate health targets at this time. In palliative dialysis, a subset within patient-centered care, treatments are chosen so that if needed, patient goals are prioritized over physician goals. One approach is to classify patients into one of three treatment groups, each with a different expected outcome: 1. Dialysis as a bridging treatment or long-term maintenance treatment, when the patient is expected to return to usual life activities 2. Although it is often necessary to adapt dialysis timings and prescriptions, and dialysis discontinuation may be a component, these interventions are rarely sufficient to ameliorate symptoms and suffering. When taking a palliative approach to renal care, advance care planning becomes of paramount importance. As the patient continues along the disease trajectory, he or she, together with the immediate family, will increasingly need support as they learn to accept death as a natural consequence. As death approaches, the focus becomes more consistent with interventions that improve the dying process and end-of-life care. In palliative dialysis, the focus of care is on the prevention and relief of suffering. Treatments are adapted to the issues that matter most to the patient and are adjusted so that the individual patient can achieve goals for the remaining life. This approach, also termed "patient-centered care," requires setting a balance between issues important to the clinician. However, it can be an option for those in whom fluid management is not a big problem and who favor spending more time at home, with reduced transportation to and from the dialysis facility over symptoms related to underdialysis. Engaging patients and families in discussions often leads to identification of the issues and symptoms that lead to a request to reduce dialysis. Some patients will feel stressed when rushing to prepare for an early morning dialysis session or when they have to change their routine to eat their midday meal earlier and their evening meal later when attending afternoon dialysis. Dosing and timing of dialysis can then be adjusted accordingly to improve dialysis tolerance. A number of symptoms can also be mitigated by more frequent, but shorter, dialysis sessions, such as sleep disorders, respiratory distress, and postdialysis fatigue. This option may be acceptable for some patients who are not distressed by the dialysis procedure itself. Association between depression and mortality in patients receiving long-term dialysis: a systematic review and meta-analysis. Guiding principles for the care of older adults with multimorbidity: an approach for c. The clinical and economic effect of vascular access selection in patients initiating hemodialysis with a catheter. Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. At the core is appreciation of the need for a better and deeper understanding of the individual to whom we are providing care before offering treatment suggestions or evaluations. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Depression in chronic kidney disease and end-stage renal disease: similarities and differences 121. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Predicting mortality in older adults with kidney disease: a pragmatic prediction model. Predialysis health, dialysis timing, and outcomes among older United States adults. Glomerular filtration rate in healthy living potential kidney donors: a meta-analysis supporting the construction of the full age spectrum equation. Senile nephrosclerosis­does it explain the decline in glomerular filtration rate with aging The association between age and nephrosclerosis on renal biopsy among healthy adults. The influence of outpatient comprehensive geriatric assessment on survival: a meta-analysis. Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Progression of kidney disease in elderly stage 3 and 4 chronic kidney disease patients. Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease. Proteinuria and rate of change in kidney function in a community-based population. Characteristics and treatment course of patients older than 75 years, reaching end-stage renal failure in France. Evaluation of the modification of diet in renal disease study equation in a large diverse population. Age and association of kidney measures with mortality and end-stage renal disease. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. Incorporating geriatric assessment into a nephrology clinic: preliminary data from two models of care. Comprehensive geriatric assessment: comparison of elderly hemodialysis patients and primary care patients. Systematic comprehensive geriatric assessment in elderly patients on chronic dialysis: a cross-sectional comparative and feasibility study. Psychometric properties of multicomponent tools designed to assess frailty in older adults: a systematic review. Community mobility among older adults with reduced kidney function: a study of life-space. Association of frailty based on self-reported physical function with directly measured kidney function and mortality. Prevalence of frailty in end-stage renal disease: a systematic review and meta-analysis. The prevalence, association, and clinical outcomes of frailty in maintenance dialysis patients. Frailty and protein-energy wasting in elderly patients with end stage kidney disease. Factors associated with frailty and its trajectory among patients on hemodialysis. Trajectories of changes over twelve years in the health status of Canadians from late middle age. Impact of chronic kidney disease on activities of daily living in community-dwelling older adults. Relationship between renal function and physical performance in elderly hospitalized patients. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. Prediction of mortality in community-living frail elderly people with long-term care needs. Development and validation of a functional morbidity index to predict mortality in communitydwelling elders. The burden and patterns of disability in activities of daily living among community-living older persons. A simple clinical tool to inform the decision-making process to refer elderly incident dialysis patients for kidney transplant evaluation. Decreased mobility after starting dialysis is an independent risk factor for short-term mortality after initiation of dialysis. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for endstage renal disease. Development of a risk stratification algorithm to improve patient-centered care and decision making for incident elderly patients with end-stage renal disease. The clinical status and survival in elderly dialysis: example of the oldest region of France. Predicting early death among elderly dialysis patients: development and validation of a risk score to assist shared decision making for dialysis initiation. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. Accidental falls and risk of mortality among older adults on chronic peritoneal dialysis. Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Acceptance of antidepressant treatment by patients on hemodialysis and their renal providers. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Patient-perceived barriers to a screening program for depression: a patient opinion survey of hemodialysis patients. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drugrelated problems. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. The cost and frequency of hospitalization for fall-related injuries in older adults. Frailty and falls among adult patients undergoing chronic hemodialysis: a prospective cohort study. A preliminary investigation of depression and kidney functioning in patients with chronic kidney disease. Association of depression and anxiety with reduced quality of life in patients with predialysis chronic kidney disease. Depression as a potential explanation for gender differences in health-related quality of life among patients on maintenance hemodialysis. Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease. Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis.

Exceptforabloodpressureof150/100mmHg treatment erectile dysfunction seroquel 50 mg order line,hisphysical examination findings and electrocardiogram were normal symptoms kidney stones purchase discount seroquel on line. Thepatientwasstartedon an amlodipine-losartan drug combination and a low dose of aspirin symptoms 7 days after conception order seroquel 300 mg on-line. He was also encouraged to monitor his blood pressure regularly and to enroll in a smoking cessation program medications while pregnant buy genuine seroquel on line. Studies have shown that amlodipine reduces hospitalization and the need for revascularization in patients with angina symptoms 0f yeast infectiion in women buy seroquel online pills. Agents That Alter Metabolism For many years, the pharmacotherapy of angina has been dependent on vasodilators and drugs that decrease heart rate and contractility. A new group of drugs has emerged that reduce angina episodes by improving myocardial metabolism without altering heart rate or blood pressure. Ranolazine has been approved as a first-line agent for chronic stable angina and is particularly useful for patients with a heart rate less than 70/min or low blood pressure. This abnormal current leads to increased sodium-calcium exchange, intracellular calcium accumulation, and increased left ventricular wall tension. Unlike other antianginal drugs, ranolazine has no effect on heart rate or blood pressure. In clinical trials, ranolazine increased exercise capacity and reduced anginal frequency and the need for nitroglycerin use, while reducing the incidence of atrial fibrillation and improving quality of life. The drug seems to be an attractive alternative or supplement to conventional antianginal agents and can be used with -blockers and nitrates. The most common side effects of ranolazine are mild dizziness, headache, nausea, and constipation. Because of its short half-life, a sustained release preparation of the drug is available. Although fatty acids are the major fuel for the heart, glucose is metabolized more efficiently and generates more energy per unit of oxygen used. Trimetazidine inhibits ketoacyl coenzyme-A thiolase, a key enzyme in the -oxidation pathway of fatty acid metabolism. The resulting decrease in fatty acid oxidation evokes a compensatory increase in glucose metabolism and reduces oxygen consumption by about 20%. If a patient has only an occasional angina episode, sublingual nitroglycerin can be used as needed to relieve acute symptoms. If episodes occur predictably with exertion, sublingual nitroglycerin or isosorbide dinitrate can be taken as a prophylactic measure just before exertion. If the severity of angina requires regular use of sublingual nitroglycerin, however, prophylactic therapy should be considered. In some cases, angiography should be performed to determine whether percutaneous coronary intervention (angioplasty) or coronary artery bypass grafting is appropriate. These patients should be considered for coronary revascularization and stent insertion. The -blockers are ineffective in treating variant angina, which is caused by coronary vasospasm. In patients with heart failure, a long-acting nitrate may be required for angina prophylaxis, because the low doses of -blockers typically used in heart failure may not prevent angina symptoms (see Chapter 12). A man with obstructive pulmonary disease requires therapy to prevent anginal attacks. Which agent prevents myocardial cell calcium overload and thereby decreases ventricular wall tension The overall mortality rate in patients with heart failure is about eight times as high as that in the normal population, and the 5-year mortality rate for patients with heart failure approaches 50%. Pathophysiology of Heart Failure Heart failure is the end stage of a number of cardiovascular disorders that ultimately impair the ability of the ventricle to fill with blood or to eject blood into the circulation. Other important causes of heart failure include hypertension, valvular disorders, arrhythmias, viral and congenital cardiomyopathy, and constrictive pericarditis. Less commonly, heart failure results from severe anemia, thiamine deficiency, or the use of certain anticancer drugs, such as doxorubicin (see Chapter 45). Over time, these disorders produce molecular and cellular changes in cardiac myocytes and connective tissue that lead to a series of structural and functional alterations in the ventricular wall. This process, known as cardiac or ventricular remodeling, is characterized by cardiac dilatation, ventricular wall thinning, interstitial fibrosis, and wall stiffness. Cardiac remodeling is believed to result primarily from the activation of neuroendocrine systems in response to myocardial ischemia, excessive stretch of muscle fibers, or other pathologic stimuli. The neuroendocrine systems implicated in this process include the renin-angiotensinaldosterone axis, the sympathetic nervous system, various inflammatory cytokines, and local mediators such as endothelin. These mediators activate biochemical pathways that induce myocyte hypertrophy, apoptosis, collagen production, fibrosis, and other effects that lead to cardiac remodeling and loss of ventricular function. Chronic sympathetic nervous system stimulation of the injured myocardium produces myocyte hypertrophy, increases production of myocardial cytokines. The hallmark of heart failure is a reduction in stroke volume and cardiac output at any given diastolic muscle fiber length, as determined by measuring the ventricular end-diastolic pressure (preload). The reduced stroke volume can be caused by diastolic dysfunction or systolic dysfunction and is manifested as an inability of the ventricles either to fill properly or to empty properly, respectively. Systolic dysfunction can result from decreased cardiac contractility secondary to a dilated or ischemic myocardium. Diastolic dysfunction can result from decreased compliance (increased stiffness) of ventricular tissue secondary to left ventricular hypertrophy or fibrosis. Hence, both systolic and diastolic heart failure can be caused or exacerbated by the process of cardiac remodeling. In cases of left ventricular failure (left-sided heart failure), the left ventricle does not adequately pump blood forward, so the pressure in the pulmonary circulation increases. Pulmonary edema reduces the diffusion of oxygen and carbon dioxide between alveoli and the pulmonary capillaries. This causes hypoxemia (deficient oxygenation of the blood) and can lead to dyspnea (difficulty in breathing), including exertional dyspnea (dyspnea provoked by exercise), orthopnea (intensified dyspnea when lying flat), and paroxysmal nocturnal dyspnea (edema-induced bronchoconstriction when sleeping). For this reason, patients with heart failure often experience symptoms of weakness and fatigue and have reduced exercise capacity. In cases of right ventricular failure (right-sided heart failure), congestion in the peripheral veins leads to ankle edema in the ambulatory patient and to sacral edema in the bedridden patient. It also leads to hepatojugular reflux, characterized by an increase in jugular vein distention when pressure is applied over the liver. Ultimately, right-sided failure can lead to left-sided failure as the left ventricle is forced to work harder in an attempt to maintain cardiac output. The reduction in cardiac output that occurs in heart failure triggers a cascade of compensatory neuroendocrine responses. The reduction in tissue perfusion activates both the sympathetic nervous system and the renin-angiotensin-aldosterone system, both of which in turn stimulate vasoconstriction. Arterial vasoconstriction increases aortic impedance to left ventricular ejection and thereby decreases cardiac output, especially in patients with a weak, dilated heart. Hence, the net result of the neuroendocrine responses is often a further Chapter 12 DrugsforHeartFailure reduction in cardiac output and an increase in circulatory congestion. Mechanisms and Effects of Drugs for Heart Failure the primary goals of drug therapy for heart failure are to improve symptoms, slow or reverse deterioration in myocardial function, and prolong survival. Drugs can also be used to treat underlying conditions, control arrhythmias, prevent thrombosis, and treat anemia. The pharmacologic agents used to treat heart failure include drugs that (1) increase cardiac output, (2) reduce pulmonary and systemic congestion, and (3) slow or reverse cardiac remodeling. Cardiac output can be increased by positively inotropic drugs that increase cardiac contractility and by vasodilators that reduce cardiac afterload and the impedance to left ventricular ejection. Diuretics are used to mobilize edematous fluid and reduce plasma volume, thereby decreasing circulatory congestion. Angiotensin and sympathetic inhibitors have been shown to favorably influence cardiac remodeling and increase survival in persons with heart failure. Each of these drugs partly counteracts the loss of myocardial function and the maladaptive responses that occur during heart failure; however, none of the current therapies, either alone or in combination, has been completely satisfactory. Because heart failure has such a high incidence and poor prognosis, a much greater effort has been expended in the search for better means to treat it. The most significant development in recent decades has been the use of angiotensin 127 inhibitors, -adrenoceptor blockers, and other agents that attenuate cardiac remodeling and reduce the mortality rate in patients with heart failure. Ultimately, however, the successful treatment of patients with heart failure may require the development of drugs that activate genes capable of repairing or replacing myocardial tissue. Drugs that increase cardiac contractility are said to have a positive inotropic effect and are commonly referred to as inotropic drugs or agents. The inotropic agents most often used in the treatment of heart failure are the digitalis glycoside called digoxin, the adrenoceptor agonist known as dobutamine, and a phosphodiesterase inhibitor named milrinone. These drugs increase cardiac contractility by increasing calcium levels in cardiac myocytes. Digoxin Despite the fact that the digitalis glycosides such as digoxin have been used to treat heart failure for more than 200 years, their effectiveness and place in therapy have been difficult to establish. Recent clinical trials indicate that digoxin provides a definite, yet limited, benefit to patients with heart failure caused by systolic dysfunction. The high sodium concentration increases the activity of the sodium-calcium exchanger (Ex), thereby causing more calcium to enter or remain inside the cardiac myocyte. Calcium activates muscle fiber shortening and increases cardiac contractility, which in turn increases stroke volume at any given fiber length (preload). Drug Properties A large number of digitalis glycosides have been isolated from the leaves of Digitalis (foxglove) plants, as well as from toad secretions. Digoxin is composed of a steroid, a lactone ring, and three sugars linked by glycosidic bonds. The steroid nucleus of digoxin is different from that of human steroids, and it lacks most of the effects produced by gonadal or adrenal steroids. The P-glycoprotein located in the luminal membrane of proximal tubule cells pumps digoxin into the urine. Because digoxin has a low therapeutic index, serum concentrations are useful in assessing the adequacy of the dosage and evaluating potential toxicity and should be in the range of 0. It has a positive inotropic effect (an increase in the force of contraction), a negative chronotropic effect (a decrease in the heart rate), and a negative dromotropic effect (a decrease in conduction velocity). Digoxin is unique in its ability to strengthen cardiac contraction while decreasing heart rate. The increase in cytoplasmic calcium stimulates the release of additional calcium from the sarcoplasmic reticulum and increases the rate of myofibril shortening (muscle contraction), and the peak systolic muscle tension. The stroke volume is the amount of blood pumped by the ventricle during each systole, and the cardiac output is the amount of blood ejected from either ventricle of the heart per minute. Digoxin increases parasympathetic nervous system activity while decreasing sympathetic activity. The positively inotropic drugs increase stroke volume at any given fiber length and thereby decrease venous pressure and preload. These abnormal depolarizations occur during or after cardiac repolarization and lead to extrasystoles (premature or coupled beats) and tachycardia (rapid beating of the heart). The afterdepolarizations appear to be caused by excessive calcium influx into cardiac cells, and they are more likely to occur after higher doses of digoxin have been given. The most common adverse effects of digoxin are gastrointestinal, cardiac, and neurologic reactions. These reactions are often associated with elevated serum concentrations and may forewarn of more serious toxicity. Hypokalemia can precipitate arrhythmias in patients receiving digoxin, and the serum potassium level should be determined immediately if arrhythmias occur in these patients. The neurologic effects of digoxin toxicity are usually caused by excessive plasma levels of the drug and include blurred vision and yellow, green, or blue chromatopsia (a condition in which objects appear unnaturally colored). Because digoxin has some estrogenic activity, it occasionally causes gynecomastia (excessive growth of male mammary glands). Because antacids and cholestyramine can reduce the absorption of digoxin and decrease its therapeutic effects, their administration should be separated from the administration of digoxin by at least 2 hours. Diltiazem, quinidine, and verapamil reduce digoxin clearance and increase serum digoxin levels by inhibiting P-glycoprotein mediated renal excretion, thereby contributing to digitalis toxicity. When digoxin is used concurrently with these drugs, only 50% of the usual dose of digoxin should be given, and serum digoxin levels should be monitored. Loop-acting and thiazide diuretics can cause hypokalemia and precipitate digitalis toxicity, because the reduced serum potassium concentration increases digitalis binding to the sodium pump. The improvement produced by digoxin in patients with systolic heart failure probably results from a combination of a modest inotropic effect and attenuation of the neuroendocrine consequences of heart failure such as increased heart rate and vasoconstriction. Digoxin is generally not used to treat diastolic heart failure because contractility is usually not impaired in this disorder. Clinical trials have shown that although digoxin does not prolong survival, it reduces symptoms and the need for hospitalization and improves quality of life of patients with heart failure. Digoxin causes an increase in parasympathetic (vagal) tone and a decrease in sympathetic tone. Toxic concentrations of digoxin may evoke afterdepolarizations throughout the heart and thereby cause extrasystoles and tachycardia. Digoxin Immune Fab An antidote for severe digoxin toxicity is available in the form of digoxin immune fab. It is made from immunoglobulin fragments taken from sheep previously immunized with a digoxin derivative. This antibody preparation is administered intravenously and can rapidly reverse digoxin toxicity by binding to digoxin.

Rationale: the low tidal volume ventilation strategy targets lower plateau airway pressures and should not exacerbate barotrauma treatment 99213 cheap 50 mg seroquel fast delivery. Ventilator dyssynchrony can be a complication of the lower tidal volumes but treatment of lyme disease buy seroquel toronto, if it occurs medications that cause tinnitus safe 300 mg seroquel, adjustment to the ventilator strategy or increased sedation may be needed treatment management company 200 mg seroquel order otc, because significant dyssynchrony may obviate the lungprotective benefits symptoms 8dp5dt order 50 mg seroquel visa. The application of high levels of positive end-expiratory pressure may decrease venous return, but this is not usually clinically significant. In the setting of the acute respiratory distress syndrome and increased dead space fraction, respiratory acidosis due to permissive hypercapnia is relatively common. This applies to questions 2 and 3: A 65-year-old woman (weight, 60 kg) is admitted to the intensive care unit with urosepsis and associated Escherichia coli bacteremia. In addition to antibiotics, she is receiving norepinephrine to achieve a mean arterial pressure of greater than 65 mm Hg and is mechanically ventilated, requiring a fraction of inspired oxygen of 40%. Which of the following would not be compatible with an optimal strategy of renal replacement therapy Intravascular refilling from the interstitium is likely to be compromised, and a strategy of aggressive ultrafiltration would exacerbate hemodynamic instability in a patient who already has septic shock and is vasopressor-dependent. If reasonably tolerated, the ultrafiltration target could be increased for subsequent sessions. The hourly effluent volume is the sum of the volume of spent dialysate, the volume ultrafiltered (and replaced 1: 1 with convective therapy), and any net ultrafiltration. This patient, who weighs 60 kg, should have a target dose of 1200 to 1500 mL/hour. The procedure is generally well-tolerated, with few side effects, but usually requires central venous catheter placement. The term "plasmapheresis" refers to the same procedure but does not use a replacement solution. Bloodletting to remove evil humors was a commonplace medical practice, in part due to a lack of understanding of disease processes and the paucity of effective therapies. By the Middle Ages, surgeons and barbers were specializing in this bloody and often painful practice and, even as late as the 19th century, bloodletting was used for nearly every infectious and malignant malady afflicting patients in the United States and Europe. The procedure was called "vividiffusion" and demonstrated the principle that the blood of a living animal could be dialyzed outside the body and then returned to the circulation. A recent study has suggested that environmental factors, including infection, may trigger disease in genetically susceptible individuals. Rapid initiation of treatment is critical because recovery of kidney function is much more likely in the early phase of disease, before oliguria develops or dialysis is required. This balance will determine whether an abnormal component can be removed sufficiently rapidly to provide clinical benefit. This occurs in parallel to the endorgan damage, so the ultimate benefit of the procedure depends on the efficiency of toxin reduction and the rate of end-organ damage. In addition to the removal of toxic proteins or replacement of deficient ones (Box 66. Overall patient survival was 81% at 1 year of follow-up (95% in those with a creatinine level less than 5. There was only 8% renal survival in patients presenting with dialysis-dependent kidney failure, and all patients who required immediate dialysis and had 100% crescents on kidney biopsy remained dialysis-dependent. However, the initial serum creatinine concentration and number of crescents were associated with outcome. There was no benefit in patients with moderate or severe kidney disease who were not dialysisdependent at presentation. Randomized controlled trials for treating renal vasculitis were included in the analysis (31 trials), and 8 included adjuvant plasma exchange. At 12 months, there was a significant reduction in the provision of dialysis in six trials with 235 patients (relative risk, 0. Results were similar in magnitude and direction after an extended follow-up of 277 weeks. In contrast to the studies of the Lupus Nephritis Collaborative Study Group and Wallace et al. One patient had a major relapse, and two others had a minor relapse at 2 and 3 years. The main adverse effect was herpes zoster; in addition, 4 of 14 women developed irreversible amenorrhea. At the end of the follow-up, the patients who received synchronized therapy had a faster remission than the other group, but renal outcomes were not superior to conventional therapy at long-term follow-up. Cryofiltration is a modified technique that reduces circulating levels of cryoproteins. In this technique, the plasma is cooled in the extracorporeal circuit to precipitate the proteins, allowing a more efficient removal of the pathogenic proteins. Recently, some trials have shown that patients treated with sofosbuvir-based, direct-acting antiviral therapy experience improvement in kidney function. Kidney biopsy is currently not required for diagnosis, but can help distinguish the various myeloma-related kidney diseases and aid in the treatment plan. Impaired kidney function can be caused by a variety of factors, including precipitation of myeloma light chains in renal tubules (Bence Jones proteins) that can lead to direct tubular toxicity. The mortality at 6 months was 20% in each group, which increased to 60% to 80% at 12 months. In patients with symptomatic hyperviscosity, cryoglobulinemia, or moderate to severe cytopenias, emphasis should be placed on achieving rapid reduction in the burden of plasma paraproteins. Treatment should be initiated as soon as possible, with a regimen including bortezomib, dexamethasone, and rituximab to achieve more rapid disease control. The hallmark clinical features of this syndrome include microangiopathic hemolytic anemia, thrombocytopenia, and organ (including kidney) injury. The pathologic features are vascular damage manifested by arteriolar and capillary thrombosis. Clinical presentation is diverse, because some patients have minimal abnormalities, whereas others are critically ill. There is a wide range of reported exchanges (3­145), with an average of 7 to 16 daily exchanges necessary to induce remission. Improvement in the platelet count may not be seen for several days, however, and improvements in kidney function often take longer. When a normal platelet count has been achieved, plasma exchange is gradually tapered by increasing the interval between treatments. Many patients (one-third to one-half) will abruptly develop recurrent thrombocytopenia and increased evidence of hemolysis when daily plasma exchanges are tapered or stopped. Some of these patients may benefit from the addition of prednisone or other immunosuppressive therapy. In this disease, the enterotoxin induces colonic vascular injury, leading to systemic absorption and activation of numerous pathways, causing endothelial cell damage over several days. Removal of a circulating factor by immunoadsorption or plasma exchange may account for the remission of the disease in some patients. Final serum creatinine concentrations in the 8 patients with functioning kidneys averaged 1. Graft survival rates were better in younger patients (89% at 5 years in patients <15 years old compared with 77% in older patients). For the period of 2001 to 2010, patient and graft survival rates for the 1427 analyzed patients were an excellent 98% and 96% for the first year and 83% and 91% after 9 years, respectively. After achieving a pretransplant A/B-antibody titer less than 1: 16, a single dose of rituximab is given 1 or 2 days prior to transplantation. Furthermore, presensitized recipients enjoy less favorable outcomes after deceased donor kidney transplantation and are at increased risk for hyperacute or acute antibody-mediated rejection and graft loss. Successful transplantation in these patients requires a desensitization protocol of the recipient to a specific donor to reduce the risk of hyperacute rejection and immediate graft loss. Immunoadsorption allows more specific and effective clearance of circulating immunoglobulins, and some authors have proposed that this technique may provide a more effective and selective antibody depletion in few hours. It has been considered as an effective strategy for rapid desensitization in deceased donor transplantation. Treatment with direct hemoperfusion column for adsorption of 2-microglobulin has been shown to improve symptoms and/or prevent the progression of dialysis-related amyloidosis in most patients. Plasma exchange is a well-established therapeutic procedure commonly used in many neurologic disorders of autoimmune cause. Therapy should be initiated early in the course of the disease to prevent continued demyelination and secondary axonal loss leading to permanent disability. Treatment consists of four to six exchanges, each removing 3 to 5 L of plasma, performed daily or every other day. Its benefits over and above supportive care have been demonstrated in two large randomized, controlled, nonblinded, multicenter trials. Other complications can occur due to hypovolemic reaction, allergy, transitory cardiac arrhythmias, nausea, and obscured vision. Due to the lack of controlled studies, it is difficult to make recommendations for the treatment of poisonings and overdoses. For most conditions, the aim of the procedure is the removal of pathologic autoantibodies or toxins; the initial treatment goal is to exchange 1 to 1. A formula that can be used to estimate plasma volume in an adult is as follows125: Estimated plasma volume (in L) = 0. The ultimate clinical success of the procedure depends on the abundance of the abnormal protein in plasma and its rate of production. The maternal IgG crosses the placenta and causes hemolysis of the fetal red cells. This leads to fetal anemia and, when severe enough, fetal death (hydrops fetalis). The centrifugation method uses centrifugal force to separate whole blood into plasma and cellular fractions according to their density. In intermittent centrifugation, sequential volumes of whole blood are removed and centrifuged; the cellular fraction is returned to the patient, and the process is repeated until the desired volume of plasma is removed. The blood is pumped from the patient at a flow rate of up to 100 mL/min into the processing unit, which consists of a bell-shaped bowl that rotates at high speed. The denser cellular blood components are centrifuged against the lateral walls and the plasma is removed through a central outlet on the top of the bowl. Each cycle removes about 500 to 700 mL of plasma; usually it is necessary to perform the process five or six times to achieve the goal of 2. As the centrifuge revolves, different blood components are separated into discrete layers, which can be harvested separately. The advantages of intermittent centrifugation include the relative simplicity of operation, portability of machines, and convenience of a single-needle peripheral venipuncture. The disadvantages include the time (the procedure typically takes >4 hours) and the relatively large extracorporeal volume removed each time. In the continuous flow centrifugation system, the blood is pumped continuously into a rapidly rotating bowl, where plasma and cells are separated. Plasma is removed at a specified rate, and the cells plus replacement fluid are returned to the patient in a continuous manner. The membrane filtration technique is based on a synthetic membrane filter composed of different pore sizes. Similar to a hemodialysis filter, the plasmapheresis filter is composed of many hollow fiber tubes made of a membrane material with relatively large pore sizes (0. Blood is pumped through the hollow fiber tubes, and the large pores are sufficient to allow passage of plasma (proteins and plasma water) while retaining cells within the hollow fiber lumen. This technique can be done using conventional or continuous hemodialysis equipment, with a blood flow rate of 100 (±20) mL/min and an optimal transmembrane pressure less than 70 mm Hg. Plasma is removed at a rate of 30 to 50 mL/min, and the infusion rate of replacement fluid is adjusted to maintain intravascular volume. Potential disadvantages of membrane filtration include activation of complement and leukocytes by the artificial membrane and the need for a central catheter to obtain adequate blood flow rates. If severe kidney failure is present, and dialysis is required, the membrane filtration method can be done in combination with conventional hemodialysis. In this technique, the plasma that has been separated by the membrane flows again through membranes with different pore diameters and filtration and adsorption characteristics, high-molecular-weight proteins are discarded, and low-molecular-weight substances, including valuable albumin, are returned to the patient. A peripheral vein allows a maximum flow of up to about 50 to 90 mL/min, so a single venous access is adequate for intermittent centrifugation, whereas continuous centrifugation techniques will require two venous access sites. For short-term procedures, this may be adequate but loss of venous access from recurrent intravenous catheters and phlebotomy in chronically ill patients is a major problem. When the membrane filtration technique is used, a central venous catheter is necessary to sustain blood flows over 70 mL/min. Central venous access can be achieved through the femoral, internal jugular, or subclavian vein; the femoral vein should be avoided if the treatment of the patient will be ambulatory. Central venous catheters have numerous long-term complications, including catheter thrombosis, catheter infection, pneumothorax, central vein thrombosis, and vein stenosis. These issues will not be discussed here; see Chapter 68 regarding the catheters used for maintenance hemodialysis. The infusion rate is adjusted according to the blood flow rate (target ratio ranges from 1: 10 to 1: 25). When the venous flux and infusion rate of citrate are slow, there is an increased risk for catheter clotting. In this case, heparin (if not contraindicated) can be used alone or in combination with citrate. However, heparin may enhance systemic anticoagulation more than expected because of the additional effect of dilution of clotting factors by the nonplasma replacement solutions. The initial loading dose of heparin (40 U/kg) is usually administered intravenously, followed by a continuous infusion (20 U/kg per hour) adjusted to maintain an adequate anticoagulation in the circuit. Cytapheresis is the removal of leukocytes or platelets in hematologic conditions with hyperleukocytosis or thrombocytosis. Cytapheresis can also be performed for sickle cell crisis; in this setting, the goal is the removal of more than 50% of hemoglobin S and replacement with normal allogenic red cells.

Purchase seroquel with a mastercard. Autoimmune Diseases - Causes Symptoms Treatments & More….

The current evidence base is mostly derived from retrospective observational cohorts treatment associates generic seroquel 300 mg buy on-line, human case reports medications 3601 50 mg seroquel buy amex, and animal studies medications available in mexico order seroquel 100 mg amex, with each having significant limitations treatment 3rd metatarsal stress fracture order seroquel discount. Fortunately medications for rheumatoid arthritis buy seroquel with visa, consensus-based expert recommendations derived from published data are now becoming available for both corporeal5,6 and extracorporeal treatments7­19 and have been endorsed by international toxicology and nephrology societies. To treat poisonings efficiently, attending physicians must know the characteristics of the poisons, their clinical effects, pharmacokinetics, and potential removal by various techniques. The purpose of this chapter is to review the fundamental concepts of poison elimination, available elimination enhancement modalities, and poisons for which the expertise of nephrologists is most likely needed. The intended goal of forced diuresis is to induce a urine output in excess of what is considered physiologic (4-5 mL/kg per hour) to enhance the renal elimination of poisons. Historically, forced diuresis is performed through volume expansion with isotonic fluids (0. Unfortunately, forced diuresis is also associated with complications, such as volume overload, pulmonary edema, cerebral edema, and electrolyte disturbances. At present, forced diuresis is never recommended in the management of acute poisonings. However, aggressive volume repletion remains warranted for some poisons to correct hypotension and/or to overcome tubular reabsorption of some offending agents. The ionized poison then becomes "trapped" in the renal tubular lumen and is eliminated in the urine. The dissociation of a weak acid or base into its ionized state is determined by its dissociation constant (pKa)-that is, the pH at which it is 50% ionized and 50% nonionized. For example, the pKa of salicylic acid is 3, so when the urinary pH is 3, salicylate exists in a 1:1 ratio of the ionized to nonionized form. The clinical efficacy of urine alkalinization depends on the relative contribution of kidney clearance to the total body clearance of active poison. If only 1% of the ingested poison is excreted unchanged in the urine, even a 10-fold increase in renal elimination will have no clinically significant effect. Urine alkalinization is generally used to enhance the excretion of salicylates and phenobarbital, but can also be used for chlorpropamide, 2,4-dichlorophenoxyacetic acid, mecoprop (methylchlorophenoxypropionic acid), diflunisal, fluoride, and methotrexate (Table 67. The rate of infusion should be adapted to the volume status and cardiac condition of the patient but can be as high as 250 mL/h. Contraindications include severe kidney disease, pulmonary edema, and cerebral edema. Complications of urine alkalinization include hypokalemia, hypocalcemia, hypernatremia, fluid overload, and pulmonary and cerebral edema, as well as metabolic alkalosis. The degree of hypokalemia may be profound because of intracellular potassium shifts and urinary potassium losses. Moreover, normokalemia is a prerequisite for urine alkalinization to be effective; in the setting of hypokalemia, potassium is reabsorbed at the collecting tubule in exchange for a hydrogen ion. Therefore, if hypokalemia remains uncorrected during urine alkalinization, not only is the nephron unable to produce alkaline urine, but the patient is also at a higher risk of developing alkalemia. It is no longer recommended because of lack of efficacy and potential complications. Multiple dosage regimens exist and usually include 50 g every 4 hours or 25 g every 2 hours until an improvement in clinical status is seen. Complications such as aspiration pneumonitis, appendicitis, and bowel obstruction due to charcoal bezoar are very rare, and their incidence increases with the number of doses given. Contraindications include intestinal perforation or obstruction, significant gastrointestinal hemorrhage, and protracted vomiting. Extracorporeal elimination of a poison is only significant if the following conditions are present: (1) it can be extracted from the plasma compartment, (2) extracorporeal clearance contributes to a significant proportion of total clearance; and (3) if the poison exerts its toxicity outside of the plasma compartment, a significant proportion of its body stores can be eliminated during the treatment. Poisons with very high molecular weights (>100,000 Da) can only be removed by adsorption or centrifugation. Hemofiltration and hemodialysis can remove only unbound poison because the poison­protein complex size exceeds the pore size of the hemofilter or dialyzer. Hemoperfusion, however, may be more effective in poisons with protein binding up to 90% to 95%, because binding to the adsorbent (activated carbon or, less commonly, a resin) competes with Table 67. The degree of protein binding can be influenced by acute alterations in poison or protein concentration and the presence of different pathologic states. Similarly, accumulation of organic acids in uremia leads to a reduction in binding sites for some xenobiotics. Furthermore, in toxic concentrations, there may be saturation of the protein binding sites. This explains why hemodialysis is not indicated for poisons such as cocaine or toluene, which have very high endogenous clearances. This mathematical relationship assumes that the body is a single homogenous compartment of water into which the drug is distributed. These can be classified by their mechanism of removal: diffusion (hemodialysis, peritoneal dialysis), convection (hemofiltration), adsorption (hemoperfusion), and centrifugation (therapeutic plasma exchange). These components include the type of dialysis membrane, its surface area, and the blood and dialysate flow rates (Box 67. However, even if the poison size is smaller than the cutoff of the membrane, larger molecules do not diffuse as freely as smaller ones, so clearance is reduced with larger molecules. New synthetic high-flux membranes and catheters now allow the removal of larger poisons considered nondialyzable 20 years ago. Because poisoned patients rarely require net ultrafiltration, the true incidence of dialytic hypotension in the toxicology setting is unknown but is more likely related to the effect of the poison, rather than to the dialysis treatment itself. The sieving coefficient is the ratio of a solute concentration in the ultrafiltrate to its respective concentration in the plasma. A solute that freely crosses the membrane has a sieving coefficient of 1, whereas a sieving coefficient of 0 means that the solute cannot cross the membrane. Although there is evidence that this combination approach may yield better results, the amount removed by the two procedures in series is usually not additive of the effect when either is used solely and may also increase the incidence of complications. Its role in poisoning is unclear but may be considered in poisons causing massive hemolysis. However, in poisoned patients, because net ultrafiltration is rarely required, and because the removal of the offending agent is urgent, intermittent therapies are usually the modality of choice. Theoretically, these devices can remove albumin-bound xenobiotics and endogenous substances. However, preliminary data have not shown their superiority in terms of clearance of theophylline, valproic acid, or phenytoin. Therefore, the prescription of any extracorporeal treatment for the purpose of poison removal should reflect these differences. Because time is usually a concern, a temporary instead of a permanent catheter is preferred, using ultrasound guidance to reduce complications and ensure patency. The dialyzer or hemofilter should have a molecular size cutoff above that of the poison to be removed. In patients at high risk of bleeding, heparin can be substituted by saline flushes. The sodium, bicarbonate, potassium, calcium, and magnesium concentrations in the dialysate (or replacement fluid) need to be adjusted according to their serum concentrations. Phosphate may also be added to the dialysate or replacement fluid to avoid hypophosphatemia. It is also recommended that periodic measurements of serum biochemistry be performed and the content of the dialysate modified accordingly. When significant toxicity is present or suspected to be prolonged, there is little risk to extend a treatment for several additional hours. Rebound may either be due to the redistribution of poison from deep compartments. In the former case, elevation of the serum concentration might reflect a concomitant decrease of the poison concentration from the toxic compartments. If rebound is thought to be worrisome, a clinician may choose to repeat an intermittent session, switch to a continuous therapy, or extend the intermittent therapy longer than the typical 4- to 6-hour treatment duration. Drugs or poisons that are most commonly responsible for poisoning-related fatalities. Physicochemical characteristics of major xenobiotics, including toxic alcohols, are shown in Table 67. It is commonly found in antifreeze, radiator fluid, solvents, hydraulic brake fluid, de-icing solutions, detergents, lacquers, and polishes. It is used as a solvent, as an intermediate of chemical synthesis during various manufacturing processes, or as an octane booster in gasoline. Products that contain methanol include windshield or glass-cleaning solutions, enamels, printing solutions, stains, dyes, varnishes, thinners, fuels, and antifreeze additives for gasoline. It is commonly found in rubbing alcohol, skin lotion, hair tonics, aftershave lotion, denatured alcohol, solvents, cements, and cleaning products. Intoxication from these alcohols occurs rapidly after exposure and usually results from oral ingestion, although inhalation of vapors83,84 and cutaneous absorption have been reported, especially in children. Metabolic acidosis results from the formation and accumulation of glycolic acid and glyoxylic acid. However, glycolate also cross-reacts with the lactate assay on some point-of-care blood analyzers, which falsely elevates lactate concentrations. In a folate-dependent step, formic acid is then transformed to water and carbon dioxide. Aldehyde dehydrogenase then rapidly converts glycoaldehyde to glycolic acid, which is followed by the slow conversion of glycolic acid to glyoxylic acid (the rate-limiting step). Cardiopulmonary symptoms may occur 12 to 24 hours after ingestion; these result from the accumulation of newly formed organic acids. Methanol can produce a Parkinson-like syndrome by damage to the putamen and subcortical white matter of the basal ganglia. Metabolic acidosis, caused by the accumulation of formate and lactate, can be severe. Vision deficits are the hallmark of methanol poisoning and usually occur 6 to 30 hours after exposure, depending on how much ethanol has been coingested. Vision deficits include blurred vision (flashes or snowstorm), central scotoma, impaired papillary response to light, decreased visual acuity, photophobia, visual field defects, and progression to complete blindness. Because the optic nerve cells possess few mitochondria and low cytochrome oxidase levels, they are extremely susceptible to the toxic effects of formic acid. Finally, isopropanol is directly toxic to myocytes and can induce severe hypotension, which is the strongest predictor of mortality in an isopropanol overdose. Because toxic alcohols are osmotically active compounds, the osmol gap, calculated as the difference between measured osmolality (by freezing point depression) and calculated osmolality, can be used as an approximation of the toxic alcohol concentration (in mmol/L), which can then be converted to mg/dL (Table 67. This estimation can be monitored serially during admission, and especially during dialysis, when precise serum concentrations are unavailable. Also, the osmol gap would remain normal if a patient presents late after ingestion, once the parent alcohol has undergone complete oxidation, because glycolic acid and formic acid do not contribute to the osmol gap. Many types of antifreeze contain sodium fluorescein, a fluorescent dye used as a marker to detect radiator leaks. Sodium fluorescein can be detected in the urine for up to 6 hours after ingestion. Characteristic test findings of isopropanol exposure include increased osmol gap, the absence of metabolic acidosis (except if lactic acidosis is present), ketonemia, ketonuria, and normoglycemia. Because toxic alcohols are rapidly absorbed from the gastrointestinal tract, and because mucosal irritation is often present, gastrointestinal decontamination is seldom performed in this context. Aspiration of the gastric contents using a nasogastric tube may be useful if the ingestion is very recent. An initial intravenous bolus (1-2 mEq/kg), followed by an infusion, if necessary, should be given to maintain an arterial pH no less than 7. When dialysis parameters are optimized (see earlier), the rate of clearance of alcohols and metabolites can reach 250 mL/min. Assuming a methanol half-life of 54 hours under fomepizole,122 a patient with an initial methanol concentration of 320 mg/dL (100 mmol/L) would need to be hospitalized 9 days until the methanol is at a safe concentration (<20 mg/dL, or 6. However, serial monitoring of the toxic alcohol concentration or osmol gap is recommended to confirm the estimation. The use of heparin should be minimized or preferably avoided in methanol-poisoned patients due to the increased risk of intracerebral hemorrhage. In overdose, salicylic acid also uncouples oxidative phosphorylation, which is a key contributor to toxicity and death. Salicylic acid is used as a topical keratolytic agent and wart remover, bismuth subsalicylate (Pepto-Bismol; 236 mg of salicylate/15 mL) is used for reflux disease, and methyl salicylate (oil of wintergreen; 98% salicylate; 1 teaspoon contains 7 g of salicylates) is used for pain relief and as a flavoring agent. Peak serum concentrations are reached within 1 hour, unless enteric-coated products are used. However, in an acute overdose, bezoar formation and pylorospasm may delay absorption and the appearance of symptoms. Normally, less than 10% of salicylate is excreted unchanged by the kidneys, and its elimination half-life is between 2 and 4 hours. This provides the rationale for urinary alkalinization to enhance the elimination of salicylates. Acute ingestions >150 mg/kg usually present with mild to moderate toxicity; >300 mg/kg, patients are at risk of severe poisoning, and exposures >500 mg/kg are potentially lethal. Hypoglycemia occurs later, with heightened cellular energy demand and uncoupling of oxidative phosphorylation. Symptoms in this setting are often more prominent than after an acute ingestion at the same salicylate concentration; such patients are often misdiagnosed as having delirium, encephalopathy, or fever of unknown origin, and they have a high mortality. Quantitative serum salicylate concentrations can generally be determined rapidly in many centers.

References

• Mehta RH, Grab JD, OiBrien SM, et al. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation. 2006;114(21):2208-2216, quiz. 8.
• Horswell BB. Condylar fractures. In Kelly JP, editor. Oral and Maxillofacial Surgery Knowledge Update. Vol 1.
• Mako EK, Mester AR, Tarjan Z, et al: Enteroclysis and spiral CT examination in diagnosis and evaluation of small bowel Crohn's disease. Eur J Radiol 35:168, 2000.
• Rosen RC, Hatzichristou D, Broderick G, et al: Clinical evaluation and symptom scales: sexual dysfunction assessment in men. In Lue TF, Basson R, Rosen R, et al, editors: Sexual medicine: sexual dysfunctions in men and women, 2004 ed, France, 2004d, Health Publications, pp 173n220. Rosen RC, Lane RM, Menza M: Effects of SSRIs on sexual function: a critical review, J Clin Psychopharmacol 19:67n85, 1999. Rosen RC, Riley A, Wagner G, et al: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction, Urology 49:822n830, 1997.